# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 21, "Diabetes Obes Metab .", "", "<http://ctro/data#Publication_80142> <http://ctro/data#hasJournal> \"Diabetes Obes Metab .\"."
1, PublicationYear, 22, 26, "2017", "", "<http://ctro/data#Publication_80142> <http://ctro/data#hasPublicationYear> \"2017\"."
2, Randomized, 107, 117, "Randomized", "", 
128, Title, 107, 312, "Randomized clinical trial comparing the efficacy and safety of treatment with the once - weekly dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor omarigliptin or the once - daily DPP - 4 inhibitor sitagliptin", "", "<http://ctro/data#Publication_80142> <http://ctro/data#hasTitle> \"Randomized clinical trial comparing the efficacy and safety of treatment with the once - weekly dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor omarigliptin or the once - daily DPP - 4 inhibitor sitagliptin\"."
3, Frequency, 189, 202, "once - weekly", "", 
4, Omarigliptin, 250, 262, "omarigliptin", "", 
5, Frequency, 270, 282, "once - daily", "", 
6, Sitagliptin, 301, 312, "sitagliptin", "", 
128, Title, 313, 396, "in patients with type 2 diabetes inadequately controlled on metformin monotherapy .", "", "<http://ctro/data#Publication_80142> <http://ctro/data#hasTitle> \"in patients with type 2 diabetes inadequately controlled on metformin monotherapy .\"."
127, Precondition, 316, 394, "patients with type 2 diabetes inadequately controlled on metformin monotherapy", "", 
7, Type2Diabetes, 330, 345, "type 2 diabetes", "", 
9, Metformin, 373, 382, "metformin", "", 
12, Author, 397, 409, "Goldenberg R", "", "<http://ctro/data#Publication_80142> <http://ctro/data#hasAuthor> \"Goldenberg R\"."
13, Author, 418, 425, "Gantz I", "", "<http://ctro/data#Publication_80142> <http://ctro/data#hasAuthor> \"Gantz I\"."
14, Author, 434, 444, "Andryuk PJ", "", "<http://ctro/data#Publication_80142> <http://ctro/data#hasAuthor> \"Andryuk PJ\"."
15, Author, 453, 465, "O ' Neill EA", "", "<http://ctro/data#Publication_80142> <http://ctro/data#hasAuthor> \"O ' Neill EA\"."
16, Author, 474, 484, "Kaufman KD", "", "<http://ctro/data#Publication_80142> <http://ctro/data#hasAuthor> \"Kaufman KD\"."
17, Author, 493, 498, "Lai E", "", "<http://ctro/data#Publication_80142> <http://ctro/data#hasAuthor> \"Lai E\"."
18, Author, 507, 514, "Wang YN", "", "<http://ctro/data#Publication_80142> <http://ctro/data#hasAuthor> \"Wang YN\"."
19, Author, 523, 536, "Suryawanshi S", "", "<http://ctro/data#Publication_80142> <http://ctro/data#hasAuthor> \"Suryawanshi S\"."
20, Author, 545, 553, "Engel SS", "", "<http://ctro/data#Publication_80142> <http://ctro/data#hasAuthor> \"Engel SS\"."
21, Canada, 640, 646, "Canada", "", "<http://ctro/data#Population_80176> <http://ctro/data#hasCountry> <http://ctro/data#Canada>."
147, ObjectiveDescription, 710, 876, "To compare the efficacy and safety of the once - weekly oral dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor omarigliptin or once - daily DPP - 4 inhibitor sitagliptin", "", "<http://ctro/data#ClinicalTrial_80157> <http://ctro/data#hasObjectiveDescription> \"To compare the efficacy and safety of the once - weekly oral dipeptidyl peptidase - 4 ( DPP - 4 ) inhibitor omarigliptin or once - daily DPP - 4 inhibitor sitagliptin\"."
22, Frequency, 752, 765, "once - weekly", "", "<http://ctro/data#Intervention_80222> <http://ctro/data#hasFrequency> \"once - weekly\"."
24, Omarigliptin, 818, 830, "omarigliptin", "", 
23, Frequency, 834, 846, "once - daily", "", "<http://ctro/data#Intervention_80228> <http://ctro/data#hasFrequency> \"once - daily\"."
25, Sitagliptin, 865, 876, "sitagliptin", "", 
147, ObjectiveDescription, 877, 966, "in patients with type 2 diabetes ( T2DM ) and inadequate glycaemic control on metformin .", "", "<http://ctro/data#ClinicalTrial_80157> <http://ctro/data#hasObjectiveDescription> \"in patients with type 2 diabetes ( T2DM ) and inadequate glycaemic control on metformin .\"."
146, Precondition, 880, 964, "patients with type 2 diabetes ( T2DM ) and inadequate glycaemic control on metformin", "", 
26, Type2Diabetes, 894, 909, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_80157> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
27, Type2Diabetes, 912, 916, "T2DM", "", 
29, Metformin, 955, 964, "metformin", "", 
158, Precondition, 991, 1138, "Patients with T2DM with a glycated haemoglobin ( HbA1c ) concentration ≥ 6 . 5 % to ≤ 9 . 0 % while on a stable dose of metformin ( ≥ 1500 mg / d )", "", "<http://ctro/data#Population_80176> <http://ctro/data#hasPrecondition> \"Patients with T2DM with a glycated haemoglobin ( HbA1c ) concentration ≥ 6 . 5 % to ≤ 9 . 0 % while on a stable dose of metformin ( ≥ 1500 mg / d )\"."
32, Type2Diabetes, 1005, 1009, "T2DM", "", 
33, HbA1c, 1017, 1037, "glycated haemoglobin", "", 
34, HbA1c, 1040, 1045, "HbA1c", "", 
35, Percentage, 1070, 1071, "%", "", 
36, Percentage, 1083, 1084, "%", "", 
37, Metformin, 1111, 1120, "metformin", "", 
157, DoseValue, 1123, 1129, "≥ 1500", "", 
155, mg, 1130, 1132, "mg", "", 
98292, Interval, 1135, 1136, "d", "", 
41, Randomized, 1144, 1154, "randomized", "", "<http://ctro/data#ClinicalTrial_80157> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
42, DoubleBlind, 1160, 1174, "double - blind", "", "<http://ctro/data#ClinicalTrial_80157> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
43, Omarigliptin, 1193, 1205, "omarigliptin", "", "<http://ctro/data#Medication_80240> <http://ctro/data#hasDrug> <http://ctro/data#Omarigliptin>."
161, DoseValue, 1206, 1208, "25", "", "<http://ctro/data#Medication_80240> <http://ctro/data#hasDoseValue> \"25\"."
46, mg, 1209, 1211, "mg", "", "<http://ctro/data#Medication_80240> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
45, Frequency, 1212, 1223, "once weekly", "", 
47, NumberPatientsArm, 1230, 1233, "322", "", "<http://ctro/data#Arm_80204> <http://ctro/data#hasNumberPatientsArm> \"322\"."
49, Sitagliptin, 1239, 1250, "sitagliptin", "", "<http://ctro/data#Medication_80247> <http://ctro/data#hasDrug> <http://ctro/data#Sitagliptin>."
162, DoseValue, 1251, 1254, "100", "", "<http://ctro/data#Medication_80247> <http://ctro/data#hasDoseValue> \"100\"."
51, mg, 1255, 1257, "mg", "", "<http://ctro/data#Medication_80247> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
52, Frequency, 1258, 1268, "once daily", "", 
48, NumberPatientsArm, 1275, 1278, "320", "", "<http://ctro/data#Arm_80213> <http://ctro/data#hasNumberPatientsArm> \"320\"."
53, Omarigliptin, 1321, 1333, "omarigliptin", "", 
54, Sitagliptin, 1356, 1367, "sitagliptin", "", 
55, HbA1c, 1380, 1385, "HbA1c", "", 
56, TimePoint, 1389, 1396, "week 24", "", 
57, Percentage, 1554, 1555, "%", "", 
58, Mean, 1572, 1576, "mean", "", 
60, HbA1c, 1586, 1591, "HbA1c", "", "<http://ctro/data#Endpoint_80184> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
62, BaseLineValue, 1596, 1601, "7 . 5", "", "<http://ctro/data#Outcome_80261> <http://ctro/data#hasBaselineValue> \"7 . 5\". <http://ctro/data#Outcome_80288> <http://ctro/data#hasBaselineValue> \"7 . 5\"."
61, Percentage, 1602, 1603, "%", "", "<http://ctro/data#Endpoint_80184> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
106245, TimePoint, 1627, 1635, "24 weeks", "", "<http://ctro/data#Outcome_80261> <http://ctro/data#hasTimePoint> \"24 weeks\". <http://ctro/data#Outcome_80288> <http://ctro/data#hasTimePoint> \"24 weeks\"."
64, LeastSquaresMean, 1642, 1667, "least squares ( LS ) mean", "", "<http://ctro/data#Endpoint_80184> <http://ctro/data#hasAggregationMethod> <http://ctro/data#LeastSquaresMean>."
65, HbA1c, 1678, 1683, "HbA1c", "", 
66, TimePoint, 1689, 1697, "baseline", "", 
181, Reduction, 1704, 1710, "0 . 47", "", "<http://ctro/data#Outcome_80261> <http://ctro/data#hasChangeValue> \"0 . 47\"."
74, Percentage, 1711, 1712, "%", "", 
69, Omarigliptin, 1720, 1732, "omarigliptin", "", 
182, Reduction, 1745, 1751, "0 . 43", "", "<http://ctro/data#Outcome_80288> <http://ctro/data#hasChangeValue> \"0 . 43\"."
75, Percentage, 1752, 1753, "%", "", 
70, Sitagliptin, 1761, 1772, "sitagliptin", "", 
71, DiffGroupAbsValue, 1818, 1826, "- 0 . 03", "", "<http://ctro/data#DiffBetweenGroups_80315> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 03\"."
72, Percentage, 1827, 1828, "%", "", 
76, ConfIntervalDiff, 1831, 1856, "95 % CI - 0 . 15 , 0 . 08", "", "<http://ctro/data#DiffBetweenGroups_80315> <http://ctro/data#hasConfIntervalDiff> \"95 % CI - 0 . 15 , 0 . 08\"."
77, LeastSquaresMean, 1942, 1949, "LS mean", "", "<http://ctro/data#Endpoint_80189> <http://ctro/data#hasAggregationMethod> <http://ctro/data#LeastSquaresMean>. <http://ctro/data#Endpoint_80324> <http://ctro/data#hasAggregationMethod> <http://ctro/data#LeastSquaresMean>."
78, TimePoint, 1962, 1970, "baseline", "", 
79, FastingPlasmaGlucose, 1974, 1996, "fasting plasma glucose", "", "<http://ctro/data#Endpoint_80324> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#FastingPlasmaGlucose>."
188, HbA1c_target, 2033, 2061, "HbA1c < 7 . 0 % or < 6 . 5 %", "", "<http://ctro/data#Endpoint_80189> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c_target>."
83, Percentage, 2047, 2048, "%", "", 
84, Percentage, 2060, 2061, "%", "", 
82, TimePoint, 2065, 2072, "week 24", "", "<http://ctro/data#Outcome_80329> <http://ctro/data#hasTimePoint> \"week 24\". <http://ctro/data#Outcome_80383> <http://ctro/data#hasTimePoint> \"week 24\"."
189, ObservedResult, 2073, 2113, "were similar in the two treatment groups", "", "<http://ctro/data#Outcome_80329> <http://ctro/data#hasObservedResult> \"were similar in the two treatment groups\". <http://ctro/data#Outcome_80383> <http://ctro/data#hasObservedResult> \"were similar in the two treatment groups\"."
98295, ObservedResult, 2116, 2149, "There were no notable differences", "", "<http://ctro/data#Outcome_80437> <http://ctro/data#hasObservedResult> \"There were no notable differences\"."
190, EndPointDescription, 2153, 2167, "adverse events", "", "<http://ctro/data#EndPointDescription_80195> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_80194> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_80195>."
85, SymptomaticHypoglycemia, 2189, 2214, "symptomatic hypoglycaemia", "", "<http://ctro/data#Endpoint_80199> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#SymptomaticHypoglycemia>."
98296, ObservedResult, 2215, 2248, "was low and similar in the groups", "", "<http://ctro/data#Outcome_80464> <http://ctro/data#hasObservedResult> \"was low and similar in the groups\"."
198, ConclusionComment, 2265, 2465, "In patients with T2DM and inadequate glycaemic control on metformin , the addition of omarigliptin 25 mg once weekly or sitagliptin 100 mg once daily led to similar improvements in glycaemic control .", "", "<http://ctro/data#ClinicalTrial_80157> <http://ctro/data#hasConclusionComment> \"In patients with T2DM and inadequate glycaemic control on metformin , the addition of omarigliptin 25 mg once weekly or sitagliptin 100 mg once daily led to similar improvements in glycaemic control .\"."
86, Type2Diabetes, 2282, 2286, "T2DM", "", 
88, Metformin, 2323, 2332, "metformin", "", 
89, Omarigliptin, 2351, 2363, "omarigliptin", "", 
194, DoseValue, 2364, 2366, "25", "", 
95, mg, 2367, 2369, "mg", "", 
91, Frequency, 2370, 2381, "once weekly", "", 
92, Sitagliptin, 2385, 2396, "sitagliptin", "", 
195, DoseValue, 2397, 2400, "100", "", 
94, mg, 2401, 2403, "mg", "", 
96, Frequency, 2404, 2414, "once daily", "", 
199, ConclusionComment, 2466, 2547, "Both agents were generally well tolerated with a low incidence of hypoglycaemia .", "", "<http://ctro/data#ClinicalTrial_80157> <http://ctro/data#hasConclusionComment> \"Both agents were generally well tolerated with a low incidence of hypoglycaemia .\"."
99, Hypoglycemia, 2532, 2545, "hypoglycaemia", "", 
100, PMID, 2709, 2717, "28093853", "", "<http://ctro/data#Publication_80142> <http://ctro/data#hasPMID> \"28093853\"."
